Allergic rhinitis is an inflammatory condition of the nasal passages, commonly triggered by allergens like pollen, dust mites, and pet dander. It affects over 400 million people globally, with prevalence rates ranging from 10% to 30% in adults and over 40% in children. Despite existing treatment options, such as antihistamines and intranasal corticosteroids, a high unmet clinical need remains for more effective therapies. Current treatments often offer limited relief, prompting ongoing research into novel approaches, including biologics and targeted therapies. The increasing focus on precision medicine and immunotherapies is expected to drive significant growth in the rhinitis drug pipeline in the coming years.
The Rhinitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into rhinitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for rhinitis. The rhinitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The rhinitis pipeline landscape will include an analysis based on efficacy and safety measures published for the trials, including their adverse effects on patients suffering from the condition, and alignment with rhinitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to rhinitis.
Rhinitis is an inflammation of the nasal mucosa, often triggered by allergens such as pollen, dust, and pet dander. It leads to symptoms like sneezing, congestion, and a runny nose. The condition is widespread, affecting both adults and children. It occurs when the immune system overreacts to harmless substances, releasing histamines and other chemicals that cause inflammation.
Rhinitis treatment focuses on symptom relief through antihistamines, nasal corticosteroids, and decongestants. Immunotherapy and biologics are emerging options for severe cases. However, current therapies provide only partial relief, highlighting the need for more effective and targeted treatments.
Allergic rhinitis is a significant global health concern, affecting over 400 million individuals, with prevalence rates ranging from 10% to 30% among adults and over 40% among children. Epidemiological studies highlight varying allergic rhinitis prevalence, such as 24.2% in Madinah (children) and 43.8% in Riyadh (adolescents). In China, regional prevalence ranges from 6.1% in Guangzhou to 19.1% in Baoding.
This section of the report covers the analysis of rhinitis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total rhinitis clinical trials.
The drug molecule categories covered under the rhinitis pipeline analysis include small molecules, monoclonal antibodies, biologics, peptides, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for rhinitis.
The EMR rhinitis report insights include the profiles of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in rhinitis clinical trials:
This section covers a detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for rhinitis. It includes product descriptions, trial IDs, study types, drug classes, modes of administration, and recruitment statuses of rhinitis drug candidates.
The Phase IV clinical trial sponsored by Sanofi aims to assess the safety and efficacy of the Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL fixed-dose combination in Indian participants with allergic rhinitis aged 12 and above. The study, expected to be completed by October 30, 2025, will enroll approximately 203 participants, and evaluate the drug's effectiveness using nasal symptoms and total symptom scores.
Inmunotek S.L. is sponsoring a Phase 3 clinical trial to assess the efficacy and safety of subcutaneous immunotherapy for mild to moderate asthma and rhinitis/rhinoconjunctivitis triggered by dust mite allergies. The trial will include 400 participants and is expected to conclude by July 2025. Its primary objective is to evaluate symptom scores and medication usage in managing the conditions.
Sponsored by Inimmune Corporation, this Phase I clinical trial investigates the safety and tolerability of INI-2004 in healthy volunteers and allergic rhinitis patients. The study aims to assess the effects of single and multiple ascending doses. The trial will involve 68 participants and is expected to conclude by November 2024.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Rhinitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for rhinitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within rhinitis pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share